Journal
THROMBOSIS RESEARCH
Volume 164, Issue -, Pages S3-S6Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2018.01.030
Keywords
Angiogenesis inhibitors; Combination therapy; Chemotherapy; PARP inhibitors; Immune checkpoint inhibitors
Categories
Funding
- Italian Association for Cancer Research (AIRC IG) [18853]
Ask authors/readers for more resources
Since the establishment of tumor angiogenesis as a therapeutic target, new, effective antiangiogenic agents have been developed. Despite their demonstrable clinical benefits, these therapies often have only a short-term effect, with limited impact on the overall survival of cancer patients. A question in the development of these drugs concerns their optimal use in combination regimens with newer therapeutic strategies. Here we review the current therapeutic settings combining anti-angiogenesis inhibitors with chemotherapy, PARP inhibitors or immune checkpoint blockers, focusing on ovarian cancer as tumor model.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available